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Abstract
Background: The internationally mandatory complement fixation test (CFT) for testing of equine
sera for the absence of glanders has repeatedly led to discrepant results. Not only do "false
positive" sera pose a problem for the diagnostician and the animal health authorities but they can
also result in significant financial losses for the animal owners.
Due to the very low prevalence of glanders in the horse population it is of major importance to
use tests with a high specificity to overcome unreliable predictive values. We have compared
formalin-fixed B. mallei whole cell antigen and a well characterised mouse monoclonal antibody with
regard to their specificity and sensitivity for glanders serodiagnosis using CFT, an indirect (i) and a
competitive (c) ELISA platform.
Results: Our results show that the CFT is still a very reliable technique in horse populations with
very low glanders prevalence. The cELISA has a high sensitivity and specificity comparable to that
of the CFT. The cELISA offers the possibility for automatisation, can be applied to non-complement
fixing sera and used for various host species.
Conclusion: The CFT is still the method of choice for testing horses for the absence of glanders.
Background
Although glanders has allegedly been eradicated from
most countries of the western hemisphere, it is endemic
among domestic animals in Africa, Asia, the Middle East
and Central and South America [1,2]. Occasional reports
on re-introduction of glanders into disease-free regions,
e.g. Germany, exist [3]. The etiologic agent of glanders is
Burkholderia mallei, a Gram-negative, nonmotile, faculta-
tive intracellular bacterium. Horses are highly susceptible
to infection and considered to be the natural reservoir, but
also mules and donkeys succumb to infection [1]. Glan-
ders affects the upper respiratory tract and the lungs which
develop granulomas that evolve into ulcers. Further symp-
toms are purulent nasal discharge, pneumonia and poor
general condition. The cutaneous form (farcy) appears on
the surface of limbs and body. Subclinically and latently
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infected carriers spread the bacterium under crowding
conditions and stress, via infected food and drinking
water or commonly used harnesses.
Within eradication programs the complement fixation
test (CFT) has been the favoured serological diagnostic
tool thanks to its ability to detect clinically in-apparent
carriers. Although negative reactions are occasionally
observed in sera of old, pregnant or worn out animals,
and false positive reactions occur in approx. 1% of the
tested horse sera (with hindsight attributable to the use of
whole cell antigen) the CFT has an excellent sensitivity of
at least 97% when compared to the gold standard pathol-
ogy [4]. But in times of low disease prevalence more
emphasis has been placed on developing tests with higher
specificity in order to avoid false positives responsible for
unnecessary restrictions in international animal transport.
When the prevalence is below 0.07% only tests with spe-
cificities of 99.995% provide reasonably accurate identifi-
cation of the disease [5]. Hence, several techniques, such
as counter-immunoelectrophoresis (CIET), western blot,
Rose Bengal test (RBT) and competitive ELISA (cELISA),
which were believed to meet this requirement, were thor-
oughly investigated. However, none of these tests fulfilled
this criterion [6-9]. These tests are either based on crude
bacterial preparations or uncharacterised monoclonal
antibodies. A recent re-evaluation study on the perform-
ance of the four serological techniques CFT, IHAT (indi-
rect hemagglutination test), RBT and modified CIET
showed that no significant improvement of sensitivity is
achieved when using crude whole cell antigens on prevail-
ing materials or currently circulating strains [10]. Conse-
quently, in order to improve test quality new analytical
test substances need to be evaluated with particular
emphasis on their immunogenetic characterisation and
their degree of purity.
This paper describes the use of a formalin-fixed B. mallei
whole cell antigen, and the well characterised B. mallei
specific monoclonal antibody 3D11 in an indirect and a
competitive ELISA for the serodiagnosis of glanders in
comparison to the CFT.
Methods
Eight hundred and six sera from imported horses and
horses due for export were included in this study and
divided into five groups (Table 1). Group I: 732 glanders-
free horses originating from various countries; group II:
ten suspect cases; group III: five horses in contact with
horses with acute glanders; group IV: 34 horses due for
import or export, of which two developed glanders; group
V: 25 malleinised horses previously in contact with a
horse in group II. Mallein was purchased from the Central
Veterinary Control and Research Institute (Etlik, Ankara,
Turkey) and 0.2 ml were injected intracutaneously (i.c.)
into the left side of the neck. No skin reaction was
observed after malleinisation. The sera were stored at the
Table 1: Comparison of the results from 806 sera investigated by means of complement fixation test, indirect and competitive ELISA
CFT iELISA cELISA
Group Origin # ccPro Dubai7 -OD
<0.125
OD
0.125-0.185
+OD
>0.185
-OD
>0.8
OD
0.775-0.800
+OD
≤ 0.775
+-+-
I Bavaria 100 0 100 0 100 65 18 17 86 3 11
Syria 164 0 164 0 164 124 18 22 159 2 3
Lebanon 15 0 15 0 15 13 1 1 15 0 0
Qatar 56 0 56 0 56 44 7 5 54 0 2
Saudi Arabia 52 0 52 0 52 34 10 8 50 0 2
Kuwait 52 0 52 0 52 40 8 4 51 1 0
K i s h 1 201 201 2 8 0 4 1 2 0 0
Mauritius 32 0 32 0 32 18 8 6 32 0 0
Bahrain 49 0 49 0 49 22 14 13 49 0 0
Dubai 82 0 82 0 82 74 6 2 81 0 1
Jordan 51 0 51 0 51 34 6 11 11 0 0
Egypt 57 0 57 0 57 42 13 2 56 0 1
O m a n 1 001 001 0 7 3 0 1 0 0 0
II Syria 10 0* 9 3 7 7 0 3 7 0 3
III Al Ain, Dubai, (contact cases) 5 4 1 5 0 0 1 4 0 0 5
IV Miscellaneous 34 dubious reactions 17 3 14 32 0 2
V Malleinised horses 25 for details see Table 2
TOTAL 806
*1 dubious reactionBMC Veterinary Research 2009, 5:32 http://www.biomedcentral.com/1746-6148/5/32
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Central Veterinary Research Laboratory (CVRL), Dubai, in
2 ml Eppendorf tubes and maintained for several years at
-20°C prior to testing.
Complement fixation test and antigen preparation
All sera were tested by the recommended CFT according to
the OIE Manual of Diagnostic Tests and Vaccines for Ter-
restrial Animals [9] using the commercially available CFT
(ccPro, Neustadt/W., Germany) and an in-house CFT
employing the antigen from a virulent B. mallei strain
(Dubai7) isolated during a glanders outbreak in Dubai in
2004 [11]. The ccPro antigen is produced according to the
standards set by the OIE Manual of Diagnostic Tests and
Vaccines for Terrestrial Animals [9]. Samples were consid-
ered negative when 100% haemolysis occurred at a 1:5
dilution, 25-75% haemolysis were considered as dubious
and no haemolysis was considered as positive [9].
Dubai7 was grown on blood agar for 72 hours. The colo-
nies were suspended in 0.9% NaCl, treated with 37% for-
malin overnight, washed with PBS, pelleted and diluted in
PBS (OD 0.2). The preserved stock antigen was main-
tained at -20°C at the CVRL. Positive control serum was
obtained from ccPro.
Selection of cut-off values for the indirect and the 
competitive ELISA
For the indirect ELISA, a cut-off was selected which was
based on the OD value observed for the weakest positive
horse. No bacterium was isolated but this animal was pos-
itive in a B. mallei specific PCR from formalinised tissue
[11]. The CFT titre of this horse was 1:20 ++ with the com-
mercially available ccPro antigen and 1:40++ with the
Dubai7 antigen. The OD value of this sample was 0.180
and was used in this ELISA as the weak positive control.
This finding resulted in the conclusion that sera showing
an OD value between 0.125 - 0.185 (round off values
0.05) could be considered as dubious reactors thus requir-
ing confirmatory analysis. The strongly reacting positive
serum came from a confirmed glanders case from which
the bacterium was isolated. The OD value of this sample
was 0.785. The serum showed a CFT titre at 1:40++++ with
the ccPro antigen and 1:80+++ with the Dubai7 antigen.
Necropsy revealed positive glanderous lesions. The PCR
results from the tissues were also positive for B. mallei. The
negative sample came from an equine foal, which tested
negative in all three tests with the lowest OD value of
0.050.
The same control sera were used for the competitive
ELISA. The strong positive control showed an OD value of
0.097 and the weak positive control showed an OD value
of 0.750, the negative control showed an OD value of
1.135. The cut-off was set at 0.775 (0.750+0.025 = 0.775)
to include putative reactors falling within this range. OD
values in the range 0.775 - 0.800 were considered as dubi-
ous reactors.
Serum analysis by means of an indirect ELISA
Subsequently, the sera were tested in an indirect ELISA
(iELISA) using the Dubai7 formalinised antigen prepara-
tion at a dilution of 1:2,000. Equine sera and the anti-
horse conjugate (Sigma, Taufkirchen, Germany) were
diluted to 1:1,000 and 1:10,000 respectively. The follow-
ing buffers were used: wash buffer 0.05% PBST, and dilu-
tion buffer 0.05% PBST + 5% milk powder and 1% bovine
serum albumin. The anti-horse IgG HRP conjugate and
substrate TMB (3,3',5,5'-tetramethylbenzidine with
sodium perborate substrate buffer) were obtained from
Sigma (Taufkirchen, Germany). All reactions were
stopped with 1 M sulphuric acid. All serum evaluations
were measured at 450 nm and readings were taken on the
SUNRISE™ Tecan machine (Crailsheim, Germany).
Serum analysis by means of an in house competitive ELISA
Sera were then analysed by means of an in-house cELISA
using the Dubai7 formalinised antigen preparation at a
dilution of 1:500. Equine sera and the anti-horse conju-
gate (Sigma, Taufkirchen, Germany) were diluted to
1:1,000 and 1:10,000, respectively. The mouse mono-
clonal antibody 3D11 (Biotrend, Köln, Germany) was
diluted 1:500. This monoclonal antibody derives from the
hybridisation of SP2/0 myeloma cells with spleen cells of
Balb/c mice immunised with a cell extract of B. mallei.
This well characterised antibody targets a B. mallei specific
epitope of the OPS [12,1]. The following buffers were
used: washing buffer 0.01 M PBS and dilution buffer 0.01
M PBS with 0.1% Tween20™ and 0.3% bovine serum
albumin. The anti-mouse HRP conjugate was used at a
dilution of 1:10,000 and visualised with the substrate
OPD (o- phenylenediamine) (both Sigma, Taufkirchen,
Germany). The reactions were stopped with 1 M sulphuric
acid. All readings were taken at 492 nm using the SUN-
RISE™ Tecan machine.
Results
In Group I, 100% specificity was observed for all samples
tested with the CFT and both antigens (ccPro and Dubai7)
(Table 1). In group II, no positive results were registered
with the ccPro antigen, 10% of the samples gave dubious
results and the rest (90%) was negative. The Dubai7 anti-
gen registered three positive but no dubious results. In
group III, 80% positive and 20% negative results were
observed for the samples tested with the ccPro antigen
and 100% were positive with the Dubai7 antigen. In
group IV, all sera of the horses showed dubious reactions
in the CFT ranging from 1:2 - 1:10. The results obtained
were independent of the antigen used (ccPro and Dubai7
antigen). In group V (Table 2), both CFTs tested horses
identically positive or negative. Prior to malleinisation allBMC Veterinary Research 2009, 5:32 http://www.biomedcentral.com/1746-6148/5/32
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25 horses were negative (ccPro and Dubai7 antigen). At
day 17, 7 horses (3, 10, 11, 16, 17, 20, 25) were negative.
At day 42, 13 horses were still positive. On day 134, 1
horse (11) was positive in the CFT and 2 horses (19, 22)
had dubious results.
In the iELISA using the Dubai7 antigen the following
results were observed: In group I, 112 (15.3%) samples
showed doubtful results, 526 (71.8%) were negative and
94 (12.9%) gave false positive results (Table 1). After
excluding the 100 Bavarian samples because of lipid con-
tamination, 94 (14.9%) dubious and 78 (12.4%) false
positive results were recorded. In group II, the iELISA
revealed 3 (30%) positive, and 7 (70%) negative results.
In group III, 4 (80%) samples were positive, and 1 (20%)
was dubious. In group IV, 14 (41.2%) positive, 3 (8.8%)
dubious and 17 (50%) negative samples were found. In
group V, all 25 horses were negative and below the cut-off
value (0.185) at day 0 prior to malleinisation. At day 17,
horses 1, 4, 9, 12, 20, 21, 22 and 24, and at day 42, horses
1, 2 and 22 were positive. On day 134, horse 22 was still
positive (Table 2). The cut-off for the iELISA was based on
the OD value observed for the weakest positive Syrian
horse in group II (0.180). The negative sample derived
from an equine foal which tested negative in the CFT,
iELISA and cELISA. The OD value was 0.050.
Analyses of the samples using the cELISA with the Dubai7
antigen and the mouse monoclonal antibody 3D11 gave
following results: In Group I, 6 (0.8%) samples showed
doubtful results, 706 (96.5%) were negative and 20
(2.7%) gave false positive results (Table 1). Upon exclu-
sion of the 100 Bavarian samples, 3 (0.47%) dubious and
9 (1.42%) false positive results were recorded. In group II
the cELISA revealed 3 (30%) positive, 7 (70%) negative
and no dubious results. In group III, 5 (100%) positive
results were recorded. In group IV, 2 (5.9%) positive, 32
(94.1%) negative but no dubious results were found. In
group V, 25 sera were negative at day 0 prior to malleini-
sation. At day 17, 6 horses (3, 6, 7, 12, 18, 22) were posi-
tive. At day 42 and 134, 1 horse (22) was still positive
(Table 2). The same control sera used in the iELISA was
also applied to the cELISA. The strong positive control
showed an OD value of 0.097 and the weakest positive
control showed an OD value of 0.750. The negative con-
trol showed an OD value of 1.135. The graphically
deduced cut-off was set at 0.775 (0.750 + 0.025 = 0.775)
to include putative reactors falling within this range. OD
Table 2: Detection of antibodies against mallein by means of serological assays over a period of 19 weeks
CFT iELISA cELISA CFT iELISA cELISA CFT iELISA cELISA CFT iELISA cELISA
Group
V
ccPro/
Dubai7
Dubai7 Dubai7/
3D11
ccPro/
Dubai7
Dubai7 Dubai7/
3D11
ccPro/
Dubai7
Dubai7 Dubai7/
3D11
ccPro/
Dubai7
Dubai7 Dubai7/
3D11
horse Day 0 Day 17 Day 42 Day 134
1 -- -+ +-+ +--- -
2- - - + - - - + - - - -
3 -- --- -+- --- -
4 -- -++++- - - -
5- - - + - - - - - - - -
6 -- -+- -+- --- -
7 -- -+- ++- - -- -
8 -- -+- ++- - -- -
9 -- -+ +-+- --- -
1 0 -- --- --- --- -
1 1 -- --- -+- -+- -
1 2 -- -++++- - -- -
13 - - - + - - + - - - - -
1 4 -- -+- --- --- -
15 - - - + - - + - - - - -
1 6 -- --- --- --- -
1 7 -- --- --- --- -
1 8 -- -+-+-- --- -
1 9 -- -+- --- - 1 : 2 - -
2 0 -- --+--- --- -
21 - - - + + - + - - - - -
2 2 -- -+ ++-++ 1 : 2 ++
23 - - - + - - + - - - - -
2 4 -- -+ +--- --- -
2 5 -- --- --- --- -
+: positive reaction;
-: negative reaction;BMC Veterinary Research 2009, 5:32 http://www.biomedcentral.com/1746-6148/5/32
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values in the range 0.775 - 0.800 were considered as dubi-
ous reactors.
Discussion
In recent years laboratories with high numbers of equine
sera for import/export testing have encountered discrep-
ant glanders results when using the internationally man-
datory CFT. Wernery et al. [13], for instance, found 0.12%
positive reactors in 22,212 sera from healthy horses tested
over a ten year period in the United Arab Emirates. These
reactors pose a logistical problem not only to the investi-
gator but also to the animal health authorities and to the
horse owner. Due to the assumed very low prevalence in
the horse population it is of major importance to use tests
with a high specificity to overcome unreliable predictive
values. We therefore investigated the influence of forma-
lin-fixed B. mallei whole cell antigen (ccPro; Dubai7) and
a well characterized mouse monoclonal antibody (3D11)
with regard to their specificity and sensitivity for glanders
serodiagnosis using an indirect and a competitive ELISA
platform and compared it to the CFT. The Dubai7 antigen
used in both ELISA was produced by formalin incubation.
The outcome of the results for the samples from "glanders
free" horses (group I) in the indirect ELISA was unex-
pected with regard to specificity (Tables 1 and 3), in par-
ticular in the Bavarian horse samples obtained from a
"disease free zone". These false positive reactions could be
attributed to the fact that the latter sera were of poor qual-
ity due to lipemic plugs. These products possibly affected
the test by non-specific blocking of antibody binding
sites. These findings also applied to the cELISA, whereas
both CFT were not affected by the quality of the sera.
Therefore, we decided to exclude the Bavarian samples for
calculating specificity (Table 3).
In group II ("suspected glanders") one serum tested 'dubi-
ous' in the ccPro CFT and was initially considered to have
reacted 'non specific', however, it tested positive with the
Dubai7 antigen. This serum and two further sera reacted
positive in both ELISA. These serologically positive horses
were confirmed to be glanderous by PCR, whereas the
remaining seven horses were serologically and PCR-nega-
tive. Interestingly, this time the iELISA was as sensitive as
the cELISA and more sensitive than the CFT. The most
likely explanation for the failure of the CFT is that during
the manufacturing process the number of reactive
epitopes is reduced by destruction or blockage. Conse-
quently, sera with low specific antibody titres are not
identified. We do not believe that B. mallei strains belong-
ing to different 'serogroups' or strains displaying a consid-
erable number of strain specific epitopes are in circulation
[1]. Genetic mutations during subcultivation in artificial
media result in the loss of LPS or CPS expression [1].
In group III ("contact cases") we observed that one serum
of a horse going through the active phase of disease was
not recognised as positive in the commercial (ccPro) CFT
but showed high titres with the Dubai7 antigen (1:160+
to 1:320+). This false negative result might be caused by
technical problems during the manufacturing process e.g.
low quality of the antigen.
The samples of group IV ("miscellaneous") represent the
classical serum panel frequently encountered when test-
ing for import/export procedures (Table 1). These samples
were collected over a 10 year period. All the sera from this
group showed titres ranging from 1: 2 to 1:10 in both CFT;
hence they were classified as dubious. Although both
ELISA use the Dubai7 antigen preparation, only the
cELISA showed 100% specificity (Table 3). The high num-
bers of dubious and false negative reactions in the iELISA
are most likely due to cross reactions with other bacterial
species with similar cell wall antigens [1,14]. This cross
reaction has been overcome by the cELISA due to the use
of a monoclonal capture antibody (3D11). Only two out
of 34 sera gave positive results. These sera came from an
import horse originating from Syria and from a horse
from Al Ain, UAE. Both were shown to be infected with B.
mallei by PCR or culture, respectively. Thus, the cELISA
clearly increases the sensitivity and specificity of disease
diagnosis in dubious CFT cases.
In group V ("malleinised horses") all the applied tests
were influenced by antibodies against mallein for up to 19
weeks after malleinisation. These findings are in accord-
Table 3: Group wise comparison of sensitivity (SN) and specificity (SP) between the serological assays in groups I-IV (figures in 
brackets include the Bavarian samples)
CFT iELISA cELISA
ccPro Dubai7 Dubai7 Dubai7/3D11
group # SN (%) SP (%) SN (%) SP (%) SN
(%)
SP
(%)
SN
(%)
SP
(%)
I 632 (732) - 100 - 100 - 85,5 (84,6) - 98,5(97,2)
II 10 50 100 100 100 100 100 100 100
III 5 80 - 100 - 80 - 100 -
IV 34 - - - - 100 58,6 100 100BMC Veterinary Research 2009, 5:32 http://www.biomedcentral.com/1746-6148/5/32
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ance with Verma et al. [15]. Although horse 22 showed
positive reactions in all serological assays up to week 19
we do not believe this animal to be affected by glanders
since this animal was clinically inconspicuous, showed no
sign of disease and did not react to the malleinisation.
Therefore, another explanation for the reaction could be a
so called 'sticky' serum. These sera are prone to unspecific
reactions and have been observed by us and other work-
ing groups [7,13,16].
We do not have an explanation for the 100% specificity of
the CFT technique in this study. It has always been
reported to be around 99%, thus up to seven false positive
results should have been found in the sera from the horses
in group I. Due to its high specificity the CFT is still a very
reliable technique especially in horse populations with
very low glanders prevalence [5]. The cELISA also has a
very promising sensitivity and specificity comparable to
that of the CFT. The major advantages of the cELISA are its
potential for automatisation and its applicability in cases
of non-complement fixing sera. Moreover, like the CFT it
can be used for various host species. We were able to test
the cELISA on human serum from a laboratory infected
person with good results (pre-infection serum: 1.009;
post-infection serum: 0.443) [17].
Conclusion
Although the CFT is an old and labour intensive tech-
nique, it still meets the requirements for diagnosing glan-
ders in a low prevalence population. However, in order to
avoid costly false positive results we recommend the com-
bined use of CFT and cELISA whenever possible.
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